|1.||Battilocchio, Claudio: 1 article (01/2014)|
|2.||Ingham, Richard J: 1 article (01/2014)|
|3.||Ley, Steven V: 1 article (01/2014)|
|4.||Hawkins, Joel M: 1 article (01/2014)|
|5.||Joyce, Michelle: 1 article (01/2012)|
|6.||Rajakulasingam, K: 1 article (01/2012)|
|7.||Bothamley, Graham H: 1 article (01/2012)|
|8.||Farah, Nima: 1 article (01/2012)|
|9.||Williams, Andrew: 1 article (01/2012)|
|10.||Roseau, J-B: 1 article (11/2008)|
11/01/2008 - "We report the observation of a patient who received Rifater for the treatment of pulmonary tuberculosis. "
11/01/2002 - "To assess the efficacy and safety of a fixed-dose combination (FDC) of Rifater (RFT)/Rifinah (RFN) in the treatment of newly diagnosed smear-positive pulmonary tuberculosis. "
11/01/2002 - "Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up."
03/11/1989 - "Nevertheless, two of them were cured with the six-month regimen containing Rifater.--Patient compliance, assessed during outpatient treatment by detecting isoniazid metabolites in the urine, was very good (93% of tests were positive in each group).--These results with a follow-up of more than 2 years, indicate that short-course therapy of 6 months duration with the fixed combination tablet may be recommended as treatment of choice in pulmonary tuberculosis except in cases of isoniazid resistance and other special situations (i.e. "
04/21/1990 - "The effectiveness of a tablet containing a combination of rifampicin, isoniazid and pyrazinamide (Rifater; Mer-National) in the treatment of pulmonary tuberculosis was examined by comparing it with a previously evaluated four-drug regimen. "
06/26/1993 - "In a controlled study at a chest hospital in Switzerland involving 261 patients with culture proven tuberculosis, the following two regimens were compared: 1) Six-month therapy (n = 128) with daily Rifater for two months, followed by H and R for four months. "
01/01/2014 - "Here we describe the use of a new open-source software package and a Raspberry Pi(®) computer for the simultaneous control of multiple flow chemistry devices and its application to a machine-assisted, multi-step flow preparation of pyrazine-2-carboxamide - a component of Rifater(®), used in the treatment of tuberculosis - and its reduced derivative piperazine-2-carboxamide. "
06/01/1995 - "From January 1988 to August 1990, 199, newly diagnosed, untreated, sputum positive tuberculosis patients were allocated randomly to two treatment groups; in Group A, 97 patients received Rifater daily for the first 2 months, followed by Rifinah daily for 4 months (2 Rifater/4 Rifinah). "
06/01/1994 - "Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town."
06/01/1995 - "A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up."
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)